Friday December 15th 2017

Patient-Reported Quality of Life in the BENEFIT Trial (P4.180)

CONCLUSIONS:PRO scores were comparable across early and delayed treatment groups and remained at high levels with only a slight decline over time in both groups. Although a bias due to only partial ascertainment of PROs and selective drop out cannot be excluded, these findings indicate an overall beneficial effect of IFNB-1b on PRO reported QoL.Study Supported by: Bayer HealthCare PharmaceuticalsDisclosure: Dr. Stolz has received personal compensation for activities with Precept Medical as an employee. Dr. Kappos has received personal compensation for activities with the University Hospital Basel. Dr. Kappos has received research support from the Swiss MS Society, Swiss National Research Foundation, the European Union, Gianni Rubatto Foundation, Novartis, and Roche Diagnostics Corp. Dr. Mo…

Continue at source – 

Patient-Reported Quality of Life in the BENEFIT Trial (P4.180)

Leave a Comment

More from category

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]

Scientists discover blood sample detection method for multiple sclerosis
Scientists discover blood sample detection method for multiple sclerosis

(University of Huddersfield) Researchers identified two natural biomarker compounds present in the blood. (Source: [Read More]

Study: The medical community isn’t prepared for the looming pandemic of neurodegenerative diseases like Parkinson’s
Study: The medical community isn’t prepared for the looming pandemic of neurodegenerative diseases like Parkinson’s

(Natural News) Parkinson’s disease is the second most common neurodegenerative disease plaguing people today, with an [Read More]